NCT05967520

JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

A Phase IIa ,Randomized, Double-blind, Placebo-controlled, Dose-exploration Study of JMKX000189 in Treatment of Moderate to Severe Active Systemic Lupus Erythematosus

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Jemincare · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.

Conditions

• Lupus Erythematosus, Systemic

Interventions

Type	Name	Description
DRUG	JMKX000189	JMKX000189 will be administered orally once a day
DRUG	Placebo	Placebo will be administered orally once a day

Timeline

• Start date: 2023-09-21
• Primary completion: 2025-05-01
• Completion: 2025-12-01
• First posted: 2023-08-01
• Last updated: 2023-10-13

Locations

17 sites across 1 country: China